

-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

GIT ASSESSMENTS								
STOOL, SPOT	Result	Range	Units					
CDSA Macroscopic Description								
Stool Colour	Brown							
Stool Form	Formed							
Mucous	NEG	< +						
Occult Blood	NEG	< +						
Macroscopy Comment	BROWN co	ploured stool is c	onsidered no	ormal in appearance.				
CDSA Microscopic Description.								
RBCs (Micro)	NEG	< +						
WBCs (Micro)	0	< 10						
Food Remnants	++ *H	< ++						
Fat Globules	NEG	< +						
Starch	NEG	< +						
CDSA Digestive Markers								
Chymotrypsin	6.5	0.9 - 26.8	U/g					
Short Chain Fatty Acids, Putrefact	ive 2.3	1.3 - 8.6	umol/g					
Meat Fibres	NEG	< +						

Microscopy Comment

Vegetable Fibres

FOOD REMNANTS PRESENT: Consider hypochlorhydria, pancreatic insufficiency, inadequate chewing.

Treatment:

• Consider hydrochloride, digestive enzymes or other digestive aids

++ *H <++

- Improve chewing
- Assess other CDSA markers such as pH, pancreatic elastase 1, H. pylori & other food fibres.

Pancreatic Elastase 1	>500	> 200	ug/g	
CDSA Absorption Markers				
Long Chain Fatty Acids	1.5	1.3 - 23.7	mg/g	



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD
NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

Digestive Markers Comment

VEGETABLE FIBRES & CELLS PRESENT:

An indirect indicator of maldigestion from insufficient chewing, gastric hypoacidity, decreased bile salts or diminished pancreatic output.

PANCREATIC ELASTASE: Normal exocrine pancreatic function.

Pancreatic Elastase reflects trypsin, chymotrypsin, amylase and lipase activity.

This test is not affected by supplements of pancreatic enzymes.

Healthy individuals produce on average 500 ug/g of PE-1. Thus, levels below 500 ug/g and above 200 ug/g suggest a deviation from optimal pancreatic function.

The clinician should therefore consider digestive enzyme supplementation if one or more of the following conditions is present:

Loose watery stools, Undigested food in the stools, Post-prandial abdominal pain, Nausea or colicky abdominal pain, Gastroesophageal reflux symptoms, Bloating or food intolerance.

CDSA Metabolic Markers

b-Glucuronidase	1767.1	337.0 - 4433.0	U/g	
pH	7.5	6.3 - 7.7		
Short Chain Fatty Acids, Beneficial	56.3	> 13.6	umol/g	•
Butyrate	23.6	10.8 - 33.5	%	
Acetate	59.4	44.5 - 72.4	%	
Propionate	15.1	0.0 - 32.0	%	
Valerate	1.9	0.5 - 7.0	%	

Metabolism Comment

In a healthy gut Short Chain Fatty Acids are exhibited in the following proportions; Butyrate, Acetate, Propionate (16% : 60% : 24%)

VALERATE:

Valerate is a short chain fatty acid that is important for gut health. Although Acetate, propionate, and butyrate make up the the most abundant SCFAs in gastrointestinal tract (95%), Valerate and other SCFA's make up the remaining and work optimally when within range.

CDSA Inflammation Markers

CDSA Tumour/Ulcer Markers

H. PYLORI, Antigen	Negative			
Calprotectin	5.9	0.0 - 50.0	ug/g	•
Eosinophil Protein X	3.6	< 7.0	ug/g	
Secretory IgA, Faecal	1119.0	400.0 - 2000.0	ng/mL	•
Transglutaminase IgA	15.0	10.0 - 100.0	ug/g	•



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD
NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

Inflammation Comment

CALPROTECTIN Normal:

Faecal calprotectin values <50 ug/g are not indicative of inflammation in the gastrointestinal tract. Subjects with low faecal calprotectin levels normally do not need to be further investigated by invasive procedures.

FAECAL TRANSGLUTAMINASE IgA: Negative

Tissue Transglutaminase is the most specific test for Coeliac Disease.

Levels less than 100 are considered NEGATIVE.

Treatment:

No treatment required. However, If there is clinical suspicion of Coeliac disease consider testing serum Coeliac markers.

Also assess IgG/IqA Food sensitivity tests to identify specific food intolerances.

M2 Pyruvate Kinase

0.6 0.0 - 4.0

units/mL



Tumour/Ulcer Comment

H. PYLORI ANTIGEN:

This test, if POSITIVE, indicates the presence of a current infection and is not affected by the presence of other organisms, antacids, barium sulphate, blood or fat. If the patient has diagnosed gastritis or a peptic ulcer consider:

- Standard triple therapy: eg. PPI, clarithromycin and amoxicillin/or metronidazole, 7-14 days
- Lactobacillus Probiotics

If the patient is asymptomatic consider natural products including:

- · Black currant seed oil and fish oil
- Lactobacillus Probiotics
- Vitamin C
- Mastic gum.

M2-PYRUVATE KINASE: Negative

M2-PK values greater than 4 U/mL may indicate gastrointestinal adenoma, colorectal cancer or other gastrointestinal carcinomas.

Tumor M2-PK has a higher sensitivity than markers CEA and CA72-4, and M2-PK values greater than 4 U/mL may indicate gastrointestinal adenoma, colorectal cancer or other gastrointestinal carcinomas.

M2-PK has a lower sensitivity and specificity in diagnosing pancreatic cancer compared to Ca 19-9. However, in patients with adenocarcinoma there is a simultaneous increase of M2-PK and Ca 19-9. In addition, M2-PK is more commonly elevated in metastatic disease and may be an additional criterium to decide on radical surgery of pancreatic cancer.

PCR for CDSA

CD Cycle No. Blasto

0.0 0.0 - 50.0

(*) Result outside normal reference range (H) Result is above upper limit of reference range

1



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date:

30-Oct-2019



3640136

	G	IT ASSESS	MENTS	
TOOL, SPOT	Result	Range	Units	
CD Cycle No. Dientamoeba	0.0	0.0 - 50.0		
		IT SENSIT		
STOOL, SPOT	Result	Range	Units	
Bifidobacteria	+++	++ - ++++		
Lactobacilli	+ *L	++ - ++++		
Escherichia coli	++++	++ - ++++		
Enterococci	+	+ - ++		
Campylobacter	NEG	< +		
Salmonella	NEG	< +		
Yersinia	NEG	< +		
Proteus	NEG	< +++		
Other Bacteria.	+++	< +++		
Candida albicans	NEG	< +		
Geotrichum spp	NEG	< +		
Rhodotorula spp	NEG	< +		
Other Yeasts	+ *H	< +		
Blastocystis Hominis	+ *H	< +		
Dientamoeba fragilis	+ *H	< +		
Cryptosporidium	NEG	< +		
Giardia lamblia	NEG	< +		
Entamoeba Histolytica	NEG	< +		
Other Parasites	NEG	< +		
Ampicillin	N/A			
Augmentin	N/A			
Ciprofloxacin	N/A			
Norfloxacin	N/A			
Meropenem	N/A			
Cephalothin	N/A			
Gentamycin.	N/A			
Trimethoprim/Sulpha	N/A			
Erythromycin	N/A			
Penicillin.	N/A			
Natural Agents				
Berberine	N/A			
Black Walnut	N/A			
Caprylic Acid	N/A			



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

GIT SENSITIVITIES					
STOOL, SPOT	Result	Range	Units		
Citrus Seed	N/A				
Coptis	N/A				
Garlic-	N/A				
Golden seal	N/A				
Oregano	N/A				



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095 44 NO Male

44 ABBOTT ROAD
NORTH CURL CURL NSW 2099

HILTON SINTON

16-Jan-2008

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

PATHOGEN SUMMARY

Clinical Notes: BROWN

OTHER BACTERIA PRESENT:

Organism Result Range Classification
The following group of organisms are deemed commensal, being neither beneficial or pathogenic. Where present, often inadequate levels of beneficial bacteria are also noted. These organisms may become dysbiotic at high levels where treatment may become necessary.

Bacteroides fragilis	3+	0 - 3+	Non-Pathogen
Staphylococcus aureus	2+	0 - 3+	Non-Pathogen
Streptococcus salivarius	3+	0 - 3+	Non-Pathogen
Streptococcus parasanguinis	2+	0 - 3+	Non-Pathogen

OTHER YEASTS PRESENT:

OTHER PARASITES PRESENT:

OrganismResultRangeClassificationBlastocystis hominis1+ * H<1+</td>PATHOGENDientamoeba fragilis1+ * H<1+</td>PATHOGEN

STAPHYLOCOCCUS AUREUS:

Sources

Foods that require considerable handling during preparation or that are kept at slightly elevated temperatures after preparation are frequently involved in staphylococcal food poisoning.

The key foods associated with staphylococcal food poisoning include meat and meat products; poultry and egg products; salads such as egg, tuna, chicken, potato, and macaroni; bakery products such as cream-filled pastries, cream pies, and chocolate eclairs; sandwich fillings; and milk and dairy products.

Pathogenicity:

Food poisoning is often attributed to the staphylococcal enterotoxin. The toxin produced by the bacteria is very heat-stable and therefore not easily destroyed by heat at normal cooking temperatures. The toxin can remain, despite the organism being destroyed. There is considerable variation in susceptibility to the enterotoxin in adults. Children and the elderly have the highest degree of susceptibility.

Symptoms:

Symptoms of staphylococcal food poisoning usually appear within 1 to 6 hours after ingestion. The individual response to the toxin may vary and depends upon the amount of contaminated food eaten, the amount of toxin ingested, and general health status.

Nausea, vomiting, abdominal cramping, and diarrhea are the most common symptoms. In more severe cases, headache, muscle cramping, and changes in blood pressure and pulse rate may occur. Recovery generally takes two days. It is not unusual for complete recovery to take three days and sometimes longer

Treatment:

In most cases, treatment for S. aureus infection is not necessary and complete recovery usually occurs after cessation of symptoms.

Other Herbal antimicrobials include:

Peppermint, Clove, Tea tree, Eucalyptus, Lemongrass, Ginger, Reishi, Red root, Quing Hao, Sida.



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD
NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

STREPTOCOCCUS:

Description:

Streptococcus is a common isolate from gut flora. With the exception of very rare cases, streptococcus species are not implicated in gastric pathogenesis. However, there has been correlations with the presence of streptococcus pyogenes in patients who have, or have recently had scarlet fever. Streptococcus species are also implicated in urinary tract infections and faecal flora are the common source of contamination for urinary tract infections.

Sources

Recent infections with streptococcus pyogenes or scarlet fever can be linked to the presence of this species in faeces.

Treatment:

Treatment of streptococcus in gut flora is not always recommended. A practitioner may take into consideration a range of patient factors and symptoms to determine if treatment is necessary.

BLASTOCYSTIS HOMINIS:

B. hominis has recently been reclassified as a protozoan, of which there are thought to be four separate serologic groups.

Sources:

This organism is transmitted via the fecal-oral route or from contaminated food or water. Prevention can be enhanced by improving personal hygiene and sanitary conditions.

Pathogenicity:

When this organism is present in the absence of any other parasites, enteric organisms or viruses, it may be considered the etiological agent of disease.

Symptoms:

Symptoms can include: diarrhea, cramps, nausea, fever, vomiting and abdominal pain. B. hominis has been associated with irritable bowel syndrome, infective arthritis and intestinal obstruction.

Treatment:

Currently, Metronidazole (Flagyl) is considered the most effective drug (750 mg tid x 10 days). Iodoquinol (Yodoxin) is also an effective medication (650 mg tid x 20 days). Recommended therapy can also eliminate G. lamblia, E. histolytica and D. fragilis, all of which may be concomitant undetected pathogens and part of patient symptomology.

DIENTAMOEBA FRAGILIS:

It is closely related to Histomonas and Trichomonas species. D. fragilis is known to cause non-invasive diarrheal illness in humans.90% of children are symptomatic, whereas only 15-20% of adults are. The most common symptoms associated with D. fragilis are intermittent diarrhea, fatigue, abdominal pain, fatigue, nausea, anorexia, malaise and unexplained eosinophilia. Diarrhea is predominately seen during the first 1-2 weeks of infection and abdominal pain may persist for 1-2 months.

Treatment:

Iodoquinol (650 mg tid \times 20 days) or Tetracycline (500 mg qid \times 10 days) or Metronidazole (500-750 mg tid \times 10 days) have been used to treat D. fragilis. Another alternative is Paromomycin (500 mg tid \times 7 days).



-.MAEVE BEARY 13 ILUKA AVENUE MANLY NSW 2095

Clinical Notes: BROWN

HILTON SINTON 16-Jan-2008 Male

44 ABBOTT ROAD NORTH CURL CURL NSW 2099

LAB ID: 3640136 UR NO.: 6552911 Collection Date: 28-Oct-2019

Received Date: 30-Oct-2019



3640136

Citrobacter	NEG	< +++	
Klebsiella	NEG	< +++	
Pseudomonas	NEG	< +++	
Streptococcus	+++	< +++	

Tests ordered: CDSA3+,IMPEI